1.10317
Fractogel® EMD BioSEC (S)
for size exclusion chromatography (SEC), suspension in 20% ethanol and 150 mM NaCl (20-40 µm)
Synonym(s):
Fractogel® EMD BioSEC (S)
Product Name
Fractogel® EMD BioSEC (S), for size exclusion chromatography (SEC), suspension in 20% ethanol and 150 mM NaCl (20-40 µm)
ligand
(Modified pore structure)
product line
Fractogel®
parameter
100 cm/hr max. flow rate
8 bar pressure
matrix active group
Methacrylate
mean particle size
20-40 μm
transition temp
flash point 35 °C (calculated)
density
1.43 g/cm3 at 20 °C
application(s)
viral therapy
separation technique
size exclusion (SEC)
storage temp.
2-30°C
Quality Level
Analysis Note
Microscopic evaluation: Uniform sphericalparticles, noagglomerates, nofines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 5.0 bar
Particle size (d10): 20 - 28 µm
Particle size (d50): 24 - 34 µm
Particle size (d90): 28 - 38 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Function test (b:a): ≤ 0.7
function test (c:d): ≤ 0.05
Functional Test: Separation of bovine serum albumin, ovalbumin and cytochrom C
Features and Benefits
- Effectively remove dimer and high molecular weight aggregates and complete an efficient polishing of blood plasma factors
- Determine apparent molecular weights of proteins
- Move predictably and efficiently from bench scale to manufacturing scale processing
- Create a robust, consistent, and transferable process
General description
Packaging
Legal Information
signalword
Warning
hcodes
Hazard Classifications
Flam. Liq. 3
Storage Class
3 - Flammable liquids
wgk
WGK 3
flash_point_f
95.0 °F
flash_point_c
35 °C
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.
A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.
Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.
This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.
Related Content
This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service